AU2020336115B2 - Characterizing methylated DNA, RNA, and proteins in subjects suspected of having lung neoplasia - Google Patents

Characterizing methylated DNA, RNA, and proteins in subjects suspected of having lung neoplasia

Info

Publication number
AU2020336115B2
AU2020336115B2 AU2020336115A AU2020336115A AU2020336115B2 AU 2020336115 B2 AU2020336115 B2 AU 2020336115B2 AU 2020336115 A AU2020336115 A AU 2020336115A AU 2020336115 A AU2020336115 A AU 2020336115A AU 2020336115 B2 AU2020336115 B2 AU 2020336115B2
Authority
AU
Australia
Prior art keywords
dna
rna
marker
methylation
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020336115A
Other languages
English (en)
Other versions
AU2020336115A1 (en
AU2020336115A8 (en
Inventor
David A. Ahlquist
Hatim T. Allawi
Maria GIAKOUMOPOULOS
Michael W. Kaiser
Graham P. Lidgard
Douglas W. Mahoney
David MALLERY
Scott Morris
William R. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exact Sciences Corp
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Exact Sciences Corp
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Exact Sciences Corp, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of AU2020336115A1 publication Critical patent/AU2020336115A1/en
Publication of AU2020336115A8 publication Critical patent/AU2020336115A8/en
Application granted granted Critical
Publication of AU2020336115B2 publication Critical patent/AU2020336115B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2020336115A 2019-08-27 2020-08-27 Characterizing methylated DNA, RNA, and proteins in subjects suspected of having lung neoplasia Active AU2020336115B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962892426P 2019-08-27 2019-08-27
US62/892,426 2019-08-27
PCT/US2020/048270 WO2021041726A1 (en) 2019-08-27 2020-08-27 Characterizing methylated dna, rna, and proteins in subjects suspected of having lung neoplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026214075 Division 2020-08-27

Publications (3)

Publication Number Publication Date
AU2020336115A1 AU2020336115A1 (en) 2022-04-14
AU2020336115A8 AU2020336115A8 (en) 2022-06-02
AU2020336115B2 true AU2020336115B2 (en) 2026-05-07

Family

ID=74686021

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020336115A Active AU2020336115B2 (en) 2019-08-27 2020-08-27 Characterizing methylated DNA, RNA, and proteins in subjects suspected of having lung neoplasia

Country Status (8)

Country Link
US (1) US20220403471A1 (cg-RX-API-DMAC7.html)
EP (1) EP4022093A4 (cg-RX-API-DMAC7.html)
JP (2) JP7902109B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220092856A (cg-RX-API-DMAC7.html)
CN (1) CN114945687A (cg-RX-API-DMAC7.html)
AU (1) AU2020336115B2 (cg-RX-API-DMAC7.html)
CA (1) CA3149601A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021041726A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673555B2 (en) 2008-02-15 2014-03-18 Mayo Foundation For Medical Education And Research Detecting neoplasm
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
EP2971179B1 (en) 2013-03-14 2019-01-09 Mayo Foundation for Medical Education and Research Detecting neoplasm
US10301680B2 (en) 2014-03-31 2019-05-28 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasm
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
JP6871926B2 (ja) 2015-08-31 2021-05-19 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチMayo Foundation for Medical Education and Research 胃の新生物を検出すること
CA3002196C (en) 2015-10-30 2024-05-14 Exact Sciences Development Company, Llc Multiplex amplification detection assay and isolation and detection of dna from plasma
US11078475B2 (en) 2016-05-03 2021-08-03 Sinai Health System Methods of capturing cell-free methylated DNA and uses of same
AU2017260630B2 (en) 2016-05-05 2023-07-13 Exact Sciences Corporation Detection of lung neoplasia by analysis of methylated DNA
AU2018211956B2 (en) 2017-01-27 2024-06-20 Exact Sciences Corporation Detection of colon neoplasia by analysis of methylated DNA
AU2018374176B2 (en) 2017-11-30 2024-12-12 Exact Sciences Corporation Detecting breast cancer
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US12548678B2 (en) 2020-05-14 2026-02-10 Ampel Biosolutions, Llc Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus
CA3127329A1 (en) 2019-01-24 2020-07-30 Mayo Foundation For Medical Education And Research Detecting endometrial cancer
JP7799607B2 (ja) 2019-10-31 2026-01-15 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 卵巣癌の検出
US11898199B2 (en) 2019-11-11 2024-02-13 Universal Diagnostics, S.A. Detection of colorectal cancer and/or advanced adenomas
AU2021257479A1 (en) 2020-04-17 2022-11-10 Exact Sciences Corporation Ingestible sampling device
WO2021228418A1 (en) 2020-05-15 2021-11-18 Universal Diagnostics, S.L. Methods and systems for identifying methylation biomarkers
US12592321B2 (en) 2020-06-19 2026-03-31 University Health Network Cancer detection and classification using methylome analysis
EP4150121A1 (en) 2020-06-30 2023-03-22 Universal Diagnostics, S.A. Systems and methods for detection of multiple cancer types
WO2023278528A1 (en) * 2021-07-02 2023-01-05 Enzo Biochem, Inc. Method for detecting and quantifying dna methylation in a selected locus or region of dna
CA3240200A1 (en) * 2021-12-10 2023-06-15 Scott V. BRATMAN Methods and systems for generating sequencing libraries
US20250361563A1 (en) * 2022-06-10 2025-11-27 Suzhou Huhu Health Technology Co., Ltd Methods, compositions, and kits for detecting malignant lung nodules and lung cancer
US12606872B2 (en) 2022-11-16 2026-04-21 Universal Diagnostics, S.A. Methods for stratification and early detection of advanced adenoma and/or colorectal cancer using DNA methylation markers
WO2024233363A2 (en) * 2023-05-05 2024-11-14 Foundation Medicine, Inc. Methods and systems for isolating nucleic acids
WO2025097008A2 (en) * 2023-11-01 2025-05-08 Nucleix Ltd. Mitochondrial dna intrinsic controls for use in msre-dependent dna methylation analysis
WO2025128887A1 (en) * 2023-12-13 2025-06-19 Foundation Medicine, Inc. Methods and compositions for selective enrichment of methylation signal
WO2025234733A1 (ko) * 2024-05-07 2025-11-13 주식회사 포어텔마이헬스 엑손-접합부를 포함하는 암 진단용 마커 및 레퍼런스 마커
WO2026055641A1 (en) 2024-09-06 2026-03-12 Exact Sciences Corporation Methods and compositions for preparing biomolecule analytes from complex samples

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009529329A (ja) * 2006-03-09 2009-08-20 トラスティーズ オブ ボストン ユニバーシティ 鼻腔上皮細胞の遺伝子発現プロファイルを用いた、肺疾患のための診断および予後診断の方法
EP3831954A3 (en) * 2008-11-17 2021-10-13 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
US20110318738A1 (en) * 2008-12-23 2011-12-29 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
EP2527459A1 (en) * 2011-05-02 2012-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Blood-based gene detection of non-small cell lung cancer
EP2520661A1 (en) * 2011-05-02 2012-11-07 Rheinische Friedrich-Wilhelms-Universität Bonn Blood-based gene expression signatures in lung cancer
AU2013207385B2 (en) * 2012-01-06 2018-09-13 Exact Sciences Corporation System and method of detecting RNAs altered by cancer in peripheral blood
EP2813850A1 (en) * 2013-06-10 2014-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting rheumatoid arthritis treatment response
WO2017181146A1 (en) * 2016-04-14 2017-10-19 Guardant Health, Inc. Methods for early detection of cancer
AU2017260630B2 (en) * 2016-05-05 2023-07-13 Exact Sciences Corporation Detection of lung neoplasia by analysis of methylated DNA
US11041214B2 (en) * 2016-05-17 2021-06-22 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
MX2021005963A (es) * 2018-11-27 2021-08-24 Exact Sciences Dev Co Llc Caracterizacion de adn metilado, arn y proteinas en la deteccion de neoplasia pulmonar.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sandoval-Pinto, E., et al. (2017): Influence of haplotypes, gene expression and soluble levels of L-selectin on the risk of acute coronary syndrome. Gene 625: 31-41. https://doi.org/10.1016/j.gene.2017.05.005 *

Also Published As

Publication number Publication date
EP4022093A1 (en) 2022-07-06
AU2020336115A1 (en) 2022-04-14
CN114945687A (zh) 2022-08-26
EP4022093A4 (en) 2024-05-22
KR20220092856A (ko) 2022-07-04
JP2022546504A (ja) 2022-11-04
US20220403471A1 (en) 2022-12-22
WO2021041726A1 (en) 2021-03-04
AU2020336115A8 (en) 2022-06-02
JP2026108791A (ja) 2026-06-30
CA3149601A1 (en) 2021-03-04
JP7902109B2 (ja) 2026-08-07

Similar Documents

Publication Publication Date Title
US20220403471A1 (en) Characterizing methylated dna, rna, and proteins in subjects suspected of having lung neoplasia
US12612664B2 (en) Detection and analysis of methylated DNA
JP7512278B2 (ja) 肺腫瘍の検出におけるメチル化dna、rna、及びタンパク質の特性決定
JP7757338B2 (ja) 乳癌の検出
JP7670662B2 (ja) メチル化dnaの分析による腫瘍の検出

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 15 , PAGE(S) 2227 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME LG ELECTRONICS INC., APPLICATION NO. 2020336115 , UNDER INID (54) CORRECT THE TITLE TO READ CHARACTERIZING METHYLATED DNA, RNA, AND PROTEINS IN SUBJECTS SUSPECTED OF HAVING LUNG NEOPLASIA